Folkert J. van Kemenade

Author

Also Known As

F J Van Kemenade, F J van Kemenade, F van Kemenade, F. A. van Kemenade, F. J van Kemenade, F. J. VAN KEMENADE, F. J. Van Kemenade, F. J. van Kemenade, F. Van Kemenade, F. van Kemenade

283

Publications

10.7K

Citations

H-Index

129

Concepts

All Affiliations

Erasmus MC Amsterdam UMC Location Vrije Universiteit Amsterdam Radboud University Nijmegen Radboud University Medical Center Amsterdam University Medical Centers

About

Folkert J. van Kemenade is an author at Erasmus MC specializing in medicine, cervical cancer, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	48	4.3K
2	Public Health	24	32	3K
3	Engineering	2	2	271
4	Natural Sciences	2	2	93
5	Social Sciences	1	1	172

Folkert J. van Kemenade

144

Publications

9.6K

Citations

H-Index

Page 1

	Year	Citations
Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial NWJ Bulkmans, Johannes Berkhof, Lawrence Rozendaal, The Lancet Cervical Cancer ScreeningOncologyCervical CancerCervical HealthHuman Papillomavirus Vaccines	2007	643
Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial Dorien Rijkaart, Johannes Berkhof, Lawrence Rozendaal, The Lancet Oncology Cervical Cancer ScreeningCervical CancerCancer DetectionHuman Papillomavirus VaccinesCancer Screening	2011	503
HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study Murat Gök, D.A.M. Heideman, Folkert J. van Kemenade, BMJ	2010	304
Endothelial cell chimerism after renal transplantation and vascular rejection Emma L. Lagaaij, Georgette Cramer-Knijnenburg, Folkert J. van Kemenade, The Lancet TransplantationKidney TransplantImmunologyEndothelial Cell ChimerismGraft Survival	2001	299
POBASCAM, a population‐based randomized controlled trial for implementation of high‐risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women Nicole W.J. Bulkmans, Lawrence Rozendaal, Peter J.F. Snijders, International Journal of Cancer	2004	265
Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma Folkert J. van Kemenade, Frank M. Raaphorst, Tjasso Blokzijl, Blood	2001	264
Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels Esther Toes‐Zoutendijk, Monique E. van Leerdam, Evelien Dekker, Gastroenterology First YearReal-time MonitoringOncologyEngineeringCancer Detection	2016	216
Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial Nicole J. Polman, Renée M.F. Ebisch, Daniëlle A.M. Heideman, The Lancet Oncology Cervical Cancer ScreeningCervical CancerCervical HealthHuman Papillomavirus VaccinesCancer Screening	2019	214
Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screening Dorien Rijkaart, Johannes Berkhof, Folkert J. van Kemenade, International Journal of Cancer	2011	212
Clinical Validation of the cobas 4800 HPV Test for Cervical Screening Purposes Daniëlle A.M. Heideman, Albertus T. Hesselink, Johannes Berkhof, Journal of Clinical Microbiology DiagnosisGynecologyCytopathologyClinical ValidationCovid-19	2011	210

Page 1